Angus Dalgleish, MD, FRCP, FRCPath

Professor of Oncology & Cancer Immunotherapy Pioneer

Academic & Clinical Training

Professor Angus Dalgleish trained at University College Hospital, where he also completed an intercalated degree in anatomy under the renowned neuroscientist Professor J. Z. Young. After his house appointments, he spent a formative year with the Flying Doctor Service in Australia, subsequently remaining to train in internal medicine and oncology at major hospitals in Brisbane and Sydney.

Retrovirology, HIV & Translational Breakthroughs


Returning to the UK in 1984, Professor Dalgleish undertook a doctoral thesis on retroviruses with Robert Weiss. He was appointed Senior Clinical Scientist at the MRC Clinical Research Centre at Northwick Park, where he advanced influential work on HIV pathogenesis and explored thalidomide as a treatment for chronic disease. His proposal that thalidomide analogues could improve efficacy while reducing toxicity led to a collaboration with Celgene, resulting in the development and licensing of lenalidomide (Revlimid) and pomalidomide (Pomalyst) for myeloma and lymphoma. For this work, he received the Joshua Lederberg Prize in 2011.

Cancer Immunotherapy & Vaccine Innovation


Since 1991, Professor Dalgleish has served as Professor of Oncology at St George’s, University of London. His career has focused on cancer immunotherapy, leading numerous clinical trials involving vaccines and immune-based treatments. Since 2001, he has been Principal of the Cancer Vaccine Institute (now the Institute for Cancer Vaccines and Immunotherapy), with current work centred on reviving mycobacterium-based vaccines, including IMM-101.

Clinical Leadership & Ongoing Research


He was Chief Investigator of a randomised trial in metastatic pancreatic cancer demonstrating a significant survival advantage for IMM-101 combined with gemcitabine, without added toxicity (BJC, 2016). His work has also shown that Revlimid can act as a co-stimulatory agent alongside vaccines, improving immune responses in HIV. Professor Dalgleish serves on multiple scientific advisory boards and receives research funding from several academic, charitable, and pharmaceutical organisations.